Contraindicated. Coadministration of doravirine with a robust CYP3A inducer may possibly decrease doravirine plasma concentrations and/or effects. Likely for lack of virologic reaction and doable resistance to doravirine.pentobarbital will decrease the level or outcome of disopyramide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/